Atara Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Thank you joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And we're pleased to have Atara Biotherapeutics here with us. With us, we have Pascal Touchon, CEO; and Jakob Dupont, Head of Research and Development.
And with that, maybe just a big picture question to start here. How are you allocating resources across your portfolio, given the expanding tab-cel program, the MS program, and the emerging Mesothelin, including rest of cell therapy program that you're developing here in parallel?
Thank you, Salveen, for your question, and good morning, good afternoon, everyone, and thank you for participating to this Atara Biotherapeutics fireside chat. Yes, we do allocate our resources appropriately according to our strategic priorities and also to deliver on the near-term milestone that we have at Atara, in particular, the initiation of the BLA for tab-cel in its first indication. Also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
